The University of Chicago Header Logo

Connection

Michael Davidson to Schizophrenia

Back to Details
This is a "connection" page, showing publications Michael Davidson has written about Schizophrenia.
Michael Davidson
Connection Strength
12.646
Schizophrenia
  1. Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence. Schizophr Bull. 2024 01 01; 50(1):14-21.
    View in: PubMed
    Score: 0.626
  2. Who has poor insight, my patient suffering from schizophrenia or myself? Eur Neuropsychopharmacol. 2023 03; 68:27-29.
    View in: PubMed
    Score: 0.585
  3. Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia. Schizophr Bull. 2022 05 07; 48(3):609-619.
    View in: PubMed
    Score: 0.558
  4. Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression. Schizophr Res. 2020 01; 215:352-356.
    View in: PubMed
    Score: 0.464
  5. The brief negative symptom scale (BNSS): Sensitivity to treatment effects. Schizophr Res. 2018 07; 197:269-273.
    View in: PubMed
    Score: 0.412
  6. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017 12 01; 174(12):1195-1202.
    View in: PubMed
    Score: 0.401
  7. A population-based longitudinal study of suicide risk in male schizophrenia patients: Proximity to hospital discharge and the moderating effect of premorbid IQ. Schizophr Res. 2015 Dec; 169(1-3):159-164.
    View in: PubMed
    Score: 0.354
  8. Bl-1020, a new ?-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J Clin Psychiatry. 2012 Sep; 73(9):e1168-74.
    View in: PubMed
    Score: 0.285
  9. CNS infection in childhood does not confer risk for later schizophrenia: a case-control study. Schizophr Res. 2010 Dec; 124(1-3):231-5.
    View in: PubMed
    Score: 0.249
  10. Refractive errors and schizophrenia. Schizophr Res. 2009 Feb; 107(2-3):238-41.
    View in: PubMed
    Score: 0.219
  11. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007 Jul; 93(1-3):117-30.
    View in: PubMed
    Score: 0.197
  12. Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006 Jul; 189:31-5.
    View in: PubMed
    Score: 0.186
  13. Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study. Schizophr Res. 2006 Jul; 85(1-3):49-57.
    View in: PubMed
    Score: 0.183
  14. Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. J Clin Exp Neuropsychol. 2006 Feb; 28(2):193-207.
    View in: PubMed
    Score: 0.181
  15. Is it Possible To Identify Patients After Their First Hospitalization for a Psychotic Disorder Who Do Not Use Anti-Psychotics and are Not Later Rehospitalized? Schizophr Bull. 2026 Jan 16; 52(1).
    View in: PubMed
    Score: 0.180
  16. Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry. 2005 Dec; 62(12):1297-304.
    View in: PubMed
    Score: 0.179
  17. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005 Oct; 162(10):1888-95.
    View in: PubMed
    Score: 0.177
  18. Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial. CNS Drugs. 2026 Jan; 40(1):99-109.
    View in: PubMed
    Score: 0.176
  19. Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). Eur Psychiatry. 2025 Aug 19; 68(1):e116.
    View in: PubMed
    Score: 0.175
  20. Body mass index and future schizophrenia in Israeli male adolescents. J Clin Psychiatry. 2004 Nov; 65(11):1546-9.
    View in: PubMed
    Score: 0.166
  21. Clinical symptoms and psychosocial functioning in patients with schizophrenia spectrum disorders testing seropositive for anti-NMDAR antibodies: a case-control comparison with patients testing negative. Lancet Psychiatry. 2024 10; 11(10):828-838.
    View in: PubMed
    Score: 0.165
  22. Prevalence of prominent and predominant negative symptoms across different criteria for negative symptom severity and minimal positive symptoms: A comparison of different criteria. Schizophr Res. 2024 09; 271:246-252.
    View in: PubMed
    Score: 0.163
  23. Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition. Eur Neuropsychopharmacol. 2024 Oct; 87:18-23.
    View in: PubMed
    Score: 0.162
  24. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry. 2004 Jul; 161(7):1219-23.
    View in: PubMed
    Score: 0.162
  25. Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study. Schizophr Bull. 2023 07 04; 49(4):903-913.
    View in: PubMed
    Score: 0.151
  26. A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2023 08; 73:65-74.
    View in: PubMed
    Score: 0.149
  27. Long-term effects of Roluperidone on negative symptoms of schizophrenia. Schizophr Res. 2023 05; 255:9-13.
    View in: PubMed
    Score: 0.148
  28. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). Lancet Psychiatry. 2023 03; 10(3):197-208.
    View in: PubMed
    Score: 0.147
  29. A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am J Psychiatry. 2002 Dec; 159(12):2027-35.
    View in: PubMed
    Score: 0.145
  30. Add-On Pramipexole for the Treatment of Schizophrenia and Schizoaffective Disorder: A Randomized Controlled Trial. J Clin Psychiatry. 2022 08 01; 83(5).
    View in: PubMed
    Score: 0.142
  31. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry. 2002; 63 Suppl 9:5-11.
    View in: PubMed
    Score: 0.136
  32. Association between nonpsychotic psychiatric diagnoses in adolescent males and subsequent onset of schizophrenia. Arch Gen Psychiatry. 2001 Oct; 58(10):959-64.
    View in: PubMed
    Score: 0.134
  33. Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs. Am J Psychiatry. 2021 10 01; 178(10):932-940.
    View in: PubMed
    Score: 0.132
  34. Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled Trials. Schizophr Bull. 2021 07 08; 47(4):1077-1087.
    View in: PubMed
    Score: 0.132
  35. Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophr Res. 2001 May 30; 50(1-2):89-93.
    View in: PubMed
    Score: 0.131
  36. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry. 2001 May; 62(5):343-6.
    View in: PubMed
    Score: 0.130
  37. Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial. Schizophr Bull. 2020 07 08; 46(4):964-970.
    View in: PubMed
    Score: 0.123
  38. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry. 2000 Jun; 15(6):506-14.
    View in: PubMed
    Score: 0.122
  39. Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial. JAMA Psychiatry. 2019 10 01; 76(10):1009-1017.
    View in: PubMed
    Score: 0.117
  40. Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial. Schizophr Res. 2019 09; 211:103-104.
    View in: PubMed
    Score: 0.115
  41. Understanding the association between advanced paternal age and schizophrenia and bipolar disorder. Psychol Med. 2020 02; 50(3):431-437.
    View in: PubMed
    Score: 0.112
  42. The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial. Schizophr Res. 2019 04; 206:325-332.
    View in: PubMed
    Score: 0.110
  43. Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. J Clin Psychiatry. 2018 May/Jun; 79(3).
    View in: PubMed
    Score: 0.106
  44. The association between adaptive and cognitive deficits in geriatric chronic schizophrenic patients. Schizophr Res. 1997 Oct 30; 27(2-3):211-8.
    View in: PubMed
    Score: 0.102
  45. Cognitive impairment in geriatric chronic schizophrenic patients: a cross-national study in New York and London. Int J Geriatr Psychiatry. 1997 Oct; 12(10):1001-7.
    View in: PubMed
    Score: 0.101
  46. Apolipoprotein E4 in schizophrenia: a study of one hundred sixteen cases with concomitant neuropathological examination. Biol Psychiatry. 1997 Aug 15; 42(4):296-8.
    View in: PubMed
    Score: 0.101
  47. Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry. 1997 Jul 15; 42(2):138-43.
    View in: PubMed
    Score: 0.100
  48. Consistency checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS). Schizophr Res. 2017 12; 190:74-76.
    View in: PubMed
    Score: 0.098
  49. Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. Schizophr Res. 1996 Dec 15; 22(3):223-31.
    View in: PubMed
    Score: 0.096
  50. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017 Mar 01; 174(3):216-229.
    View in: PubMed
    Score: 0.096
  51. Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. Am J Psychiatry. 1996 Oct; 153(10):1274-9.
    View in: PubMed
    Score: 0.095
  52. Developmental Trajectories of Impaired Community Functioning in Schizophrenia. JAMA Psychiatry. 2016 Jan; 73(1):48-55.
    View in: PubMed
    Score: 0.090
  53. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophr Bull. 2016 Jan; 42(1):19-33.
    View in: PubMed
    Score: 0.088
  54. The cost of cognitive impairment in schizophrenia. Schizophr Res. 1995 Sep; 17(1):1-3.
    View in: PubMed
    Score: 0.088
  55. Cognitive functioning in chronically hospitalized schizophrenic patients: age-related changes and age disorientation as a predictor of impairment. Schizophr Res. 1995 Sep; 17(1):15-24.
    View in: PubMed
    Score: 0.088
  56. The association between negative symptoms, psychotic experiences and later schizophrenia: a population-based longitudinal study. PLoS One. 2015; 10(3):e0119852.
    View in: PubMed
    Score: 0.085
  57. The puzzle of processing speed, memory, and executive function impairments in schizophrenia: fitting the pieces together. Biol Psychiatry. 2015 Dec 01; 78(11):786-93.
    View in: PubMed
    Score: 0.085
  58. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry. 1995 Feb; 152(2):197-207.
    View in: PubMed
    Score: 0.084
  59. Memory functions in geriatric chronic schizophrenic patients: a neuropsychological study. J Neuropsychiatry Clin Neurosci. 1995; 7(2):207-12.
    View in: PubMed
    Score: 0.084
  60. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):8942-6.
    View in: PubMed
    Score: 0.077
  61. Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am. 1993 Jun; 16(2):313-38.
    View in: PubMed
    Score: 0.075
  62. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013 Nov; 39(6):1230-41.
    View in: PubMed
    Score: 0.075
  63. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res. 2013 Jun; 147(1):132-139.
    View in: PubMed
    Score: 0.074
  64. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res. 1993 Feb; 46(2):151-63.
    View in: PubMed
    Score: 0.073
  65. Leukotomy and aging in chronic schizophrenia: a followup study 40 years after psychosurgery. Schizophr Bull. 1993; 19(4):723-32.
    View in: PubMed
    Score: 0.073
  66. Family history of schizophrenia and bipolar disorder as risk factors for autism. Arch Gen Psychiatry. 2012 Nov; 69(11):1099-1103.
    View in: PubMed
    Score: 0.072
  67. Dedifferentiation and substitute strategy: deconstructing the processing-speed impairment in schizophrenia. Schizophr Res. 2012 Dec; 142(1-3):129-36.
    View in: PubMed
    Score: 0.072
  68. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012 Jun; 73(6):e728-34.
    View in: PubMed
    Score: 0.070
  69. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991 Nov; 148(11):1474-86.
    View in: PubMed
    Score: 0.067
  70. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry. 1991 Oct; 48(10):910-3.
    View in: PubMed
    Score: 0.067
  71. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry. 1991 Jan; 48(1):73-6.
    View in: PubMed
    Score: 0.064
  72. Strong synaptic transmission impact by copy number variations in schizophrenia. Proc Natl Acad Sci U S A. 2010 Jun 08; 107(23):10584-9.
    View in: PubMed
    Score: 0.061
  73. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 1990; 14(6):879-84.
    View in: PubMed
    Score: 0.059
  74. Measurement of plasma homovanillic acid concentrations in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 1990; 14(3):271-87.
    View in: PubMed
    Score: 0.059
  75. Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2010 Jan; 71(1):58-65.
    View in: PubMed
    Score: 0.058
  76. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009 Dec; 115(2-3):97-103.
    View in: PubMed
    Score: 0.058
  77. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009 Jun; 166(6):675-82.
    View in: PubMed
    Score: 0.056
  78. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010 May; 36(3):504-9.
    View in: PubMed
    Score: 0.054
  79. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry. 1988 Jun; 45(6):561-3.
    View in: PubMed
    Score: 0.053
  80. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006 Jul; 85(1-3):254-65.
    View in: PubMed
    Score: 0.046
  81. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry. 2004 Sep; 19(9):898-905.
    View in: PubMed
    Score: 0.041
  82. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004; 65 Suppl 7:4-18; quiz 19-20.
    View in: PubMed
    Score: 0.039
  83. Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res. 1999 Jan 04; 35(1):77-84.
    View in: PubMed
    Score: 0.028
  84. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry. 1998 Aug; 155(8):1080-6.
    View in: PubMed
    Score: 0.027
  85. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry. 1998 Mar; 55(3):205-11.
    View in: PubMed
    Score: 0.026
  86. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry. 1997 Jun; 54(6):559-66.
    View in: PubMed
    Score: 0.025
  87. Characteristics of elderly psychiatric patients retained in a state hospital during downsizing: a prospective study with replication. Int J Geriatr Psychiatry. 1997 Apr; 12(4):474-80.
    View in: PubMed
    Score: 0.024
  88. Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. Am J Psychiatry. 1997 Feb; 154(2):205-10.
    View in: PubMed
    Score: 0.024
  89. Social-Adaptive Functioning Evaluation (SAFE): a rating scale for geriatric psychiatric patients. Schizophr Bull. 1997; 23(1):131-45.
    View in: PubMed
    Score: 0.024
  90. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. Biol Psychiatry. 1996 Oct 15; 40(8):755-60.
    View in: PubMed
    Score: 0.024
  91. Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. Am J Psychiatry. 1996 Jun; 153(6):806-11.
    View in: PubMed
    Score: 0.023
  92. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry. 1996 Jan 15; 39(2):82-91.
    View in: PubMed
    Score: 0.023
  93. Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Res. 1995 Nov 29; 59(1-2):127-36.
    View in: PubMed
    Score: 0.022
  94. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res. 1995 Sep; 17(1):25-33.
    View in: PubMed
    Score: 0.022
  95. Validity and utility of the ADAS-L for measurement of cognitive and functional impairment in geriatric schizophrenic inpatients. J Neuropsychiatry Clin Neurosci. 1995; 7(1):76-81.
    View in: PubMed
    Score: 0.021
  96. Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine. Biol Psychiatry. 1994 Jun 15; 35(12):909-12.
    View in: PubMed
    Score: 0.020
  97. Cortical cholinergic markers in schizophrenia. Schizophr Res. 1994 May; 12(2):137-44.
    View in: PubMed
    Score: 0.020
  98. Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophr Res. 1994 Feb; 11(3):217-24.
    View in: PubMed
    Score: 0.020
  99. Alzheimer's-disease-related protein in geriatric schizophrenic patients with cognitive impairment. Am J Psychiatry. 1993 Nov; 150(11):1726-7.
    View in: PubMed
    Score: 0.019
  100. Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry. 1993 Sep; 150(9):1337-42.
    View in: PubMed
    Score: 0.019
  101. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry. 1993 Aug; 50(8):599-605.
    View in: PubMed
    Score: 0.019
  102. Schizophrenia-related and affective personality disorder traits in relatives of probands with schizophrenia and personality disorders. Am J Psychiatry. 1993 Mar; 150(3):435-42.
    View in: PubMed
    Score: 0.018
  103. Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study. Biol Psychiatry. 1993 Feb 15; 33(4):255-60.
    View in: PubMed
    Score: 0.018
  104. Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology (Berl). 1993; 112(1 Suppl):S90-4.
    View in: PubMed
    Score: 0.018
  105. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms. Psychiatry Res. 1992 Nov; 44(2):153-65.
    View in: PubMed
    Score: 0.018
  106. Assessment of dementia in elderly schizophrenics with structured rating scales. Schizophr Res. 1992 Apr; 7(1):85-90.
    View in: PubMed
    Score: 0.017
  107. Effect of concurrent distraction on communication failures in schizophrenic patients. II. Medication status correlations. Schizophr Res. 1991 Sep; 5(2):153-9.
    View in: PubMed
    Score: 0.017
  108. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Res. 1991 Sep; 38(3):285-92.
    View in: PubMed
    Score: 0.017
  109. Time course and clinical predictors of treatment response in schizophrenia. Schizophr Res. 1991 Sep; 5(2):161-6.
    View in: PubMed
    Score: 0.017
  110. Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance. Psychiatry Res. 1991 Apr; 37(1):47-56.
    View in: PubMed
    Score: 0.016
  111. Impaired reading comprehension and mathematical abilities in male adolescents with average or above general intellectual abilities are associated with comorbid and future psychopathology. J Nerv Ment Dis. 2007 Nov; 195(11):883-90.
    View in: PubMed
    Score: 0.013
  112. Paternal age and intelligence: implications for age-related genomic changes in male germ cells. Psychiatr Genet. 2005 Jun; 15(2):117-25.
    View in: PubMed
    Score: 0.011
  113. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005 May; 162(5):947-53.
    View in: PubMed
    Score: 0.011
  114. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry. 2002; 63 Suppl 9:25-9.
    View in: PubMed
    Score: 0.009
  115. Galanin-like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease. J Neurochem. 1994 Apr; 62(4):1516-23.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.